Sanofi and Teva report positive 44-week duvakitug data in ulcerative colitis and Crohn’s disease.
The October 20 headline reports positive 44-week data for duvakitug in both conditions. But the supplied information doesn’t include trial results, patient numbers, measured outcomes, or next steps. The headline alone doesn’t show how large or broad the reported benefit was.
Investor takeaway: This is a clinical-development update, but there isn’t enough detail to assess the findings or what they mean for Sanofi.
Advertisement
Sanofi ADR
SNY.US
SNY.US
Sanofi ADR
WealthAwesomeMarket cap
$99.68B
P/E
21.9x
Div. yield
9.82%
Div. / share
$4.12
52W high
$49.91
52W low
$39.07
1W change
+2.44%
Beta
0.28
Analyst Price Targets
Based on 11 analysts covering SNY · as of Oct 19, 2026
Wall Street analysts forecast SNY stock price to rise 179.8% over the next 12 months.
Consensus
Buy3.91 / 5.00
Avg. Target
C$53.61
+179.8% Upside
Current Price
C$19.16
Last close
Analyst Breakdown (11 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on SNY's historical volatility
30-Day Vol
25.1%
Annualized
90-Day Vol
23.5%
Annualized
Trend (90d)
-12.8%
Annualized drift
90d Mean
C$39.74
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$40.97 | C$37.57 – C$44.67 |
| 60 trading days | C$40.35 | C$35.70 – C$45.60 |
| 90 trading days | C$39.74 | C$34.21 – C$46.16 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
44 weeks
The headline gives the duration of the data, but not the clinical measurements behind it.
Bull case
The headline reports positive 44-week data for duvakitug in two inflammatory bowel diseases, making this a favorable clinical update.
Bear case
The supplied information includes no efficacy measurements, safety details, trial design, regulatory status, or development timeline. That limits what investors can conclude.
What happened: positive 44-week duvakitug data
The October 20 headline says Teva Pharmaceuticals and Sanofi reported positive 44-week data for duvakitug in ulcerative colitis and Crohn’s disease. It doesn’t say which outcomes the studies measured, how patients responded, whether results differed between the conditions, or what safety findings emerged. The supplied information also omits the trial names, study sizes, comparison groups, and any regulatory update. So this is a clinical-data headline, not a detailed account of the results.
Advertisement
What the numbers show: limited detail on the clinical findings
The only number provided for the clinical update is the 44-week duration. No efficacy or safety figures are included.
Sanofi’s supplied market data show a last close of US$41.75, down 0.86% for the day. Trading volume was 607,742 shares, or 0.55 times the 20-day average of 3,658,152. These figures describe the stock, but they don’t show that the duvakitug headline caused the price move or trading volume. Sanofi shares were also 25% of the way through their 52-week range of US$39.07 to US$49.91. See Sanofi’s stock page for SNY.US.
What to watch next: fuller results and development details
More detail is needed to assess the update, including the outcomes measured, study size and design, safety results, and any next steps for duvakitug. The supplied information gives no timeline, so it doesn’t identify a specific upcoming milestone. Further company disclosures will be needed to clarify what the 44-week findings mean for the program. See Sanofi’s SNY.US stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
